Astellas Pharma S.A.S
Basic information
- Head office
- Tokyo
- Chief executive
- Naoki Okamura
- Capital
- Employees (non-consolidated)
- Employees (consolidated)
- Start date
- End date
Websites
Business
Related companies
| Company name | Group | Parent | Subsidiary | Customer | Supplier | Alliance | Bank | Shareholder |
|---|---|---|---|---|---|---|---|---|
| 安川電機株式会社 | ||||||||
|
|
||||||||
| Avara Norman Pharmaceutical Services, Inc. | ||||||||
|
|
||||||||
| Nippon Medical & Pharmaceutical Co., Ltd. | ||||||||
| OSI Pharmaceuticals, Inc | ||||||||
| OSI Pharmaceuticals社 | ||||||||
|
|
||||||||
| Takeda Pharmaceutical Company, Limited | ||||||||
|
|
||||||||
| Takeda Teba Yakuhin Co., Ltd. | ||||||||
| アステラス ファーマ グローバル ディベロップメント Inc. | ||||||||
| アステラス ファーマ ヨーロッパ B.V. | ||||||||
| アステラス ファーマ ヨーロッパ Ltd. | ||||||||
|
|
||||||||
|
|
||||||||
| アストレージ社 | ||||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
| 山之内薬品商会 | ||||||||
|
|
||||||||
|
|
||||||||
| 旭化成株式会社 | ||||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
|
|
Network
History
The company changed its name from Yamanoi Pharmacy Trading Company to Yamanoi Pharmaceutical Co., Ltd.![]()
Yamanoi Pharmaceutical established Yamanoi Ireland Co., Ltd in Europe, its first overseas active pharmaceutical ingredient production site.![]()
Yamanoi Pharmaceutical acquired the pharmaceutical division of Royal Hist Brokades in the Netherlands.![]()
Yamanoi Pharmaceutical released the urinary dysfunction improvement drug Harunair, now sold in over 90 countries. Fujisawa Pharmaceutical released the immunosuppressant Prograf, now sold in about 100 countries.![]()
Fujisawa Pharmaceutical released the atopic dermatitis treatment drug Protopic, now sold in about 60 countries.![]()
Yamanoi Pharmaceutical established Yamanoi Pharma America Inc. in the United States, creating its own sales base there.![]()
Yamauchi Pharmaceutical released the overactive bladder treatment Vesicare in Europe, and in 2005 also released it in the United States. The two companies integrated their over-the-counter pharmaceutical businesses and established Zepra.![]()
The merger of Yamauchi Pharmaceutical (formerly) and Fujisawa Pharmaceutical Industries (formerly) led to the establishment of Astellas Pharma Inc.![]()
In April 2005, Astellas was founded through the merger of Yamanouchi Pharmaceutical and Fujisawa Pharmaceutical. The strengths of Yamanouchi Pharmaceutical in urology and synthetic technology, and Fujisawa Pharmaceutical in transplantation, immunology, and fermentation technology were combined to form an optimal partnership that complements each other.![]()
The leaders of Yamanouchi Pharmaceutical and Fujisawa Pharmaceutical shook hands to commemorate the 2005 merger. Through this merger, Astellas was founded, shaping a global strategy centered on patients.![]()
Astellas was established in April 2005 through the merger of two companies – Yamanouchi Pharmaceutical (founded in 1923) and Fujisawa Pharmaceutical (founded in 1894).![]()
Zepra Co., Ltd., which conducted over-the-counter pharmaceutical business, was transferred to Daiichi Sankyo Co., Ltd.![]()
The oral quinolone synthetic antibacterial Geninack™ was launched in Japan, and Agensys, a U.S. biotech venture, was acquired.![]()
Betanis™ for overactive bladder was launched in Japan, and the company signed the UN Global Compact.![]()
Wind power was installed at the Kelly plant in Ireland, and a wood biomass boiler began operation. The company joined a new public-private partnership for developing schistosomiasis treatment for preschool children. XTANDI™ for prostate cancer was launched in the United States.![]()
In April 2025, Astellas Pharma celebrated its 20th anniversary. Astellas was founded in April 2005 through the merger of Yamanouchi Pharmaceutical, established in 1923, and Fujisawa Pharmaceutical, established in 1894. The strengths of Yamanouchi Pharmaceutical in urology and synthetic technology, and Fujisawa Pharmaceutical in transplantation, immunology, and fermentation technology were combined to form an optimal partnership that complements each other.![]()
News
There is no news.